SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells

Cell Stem Cell

Volumn 15, Issue 4, 2014, Pages 431-446

  Li, Ling ^a   Osdal, Tereza ^b   Ho, Yinwei ^a   Chun, Sookhee ^a   McDonald, Tinisha ^a   Agarwal, Puneet ^a   Lin, Allen ^a   Chu, Su ^a   Qi, Jing ^a   Li, Liang ^a   Hsieh, Yao Te ^a   Santos, Cedric Dos ^a   Yuan, Hongfeng ^a   Ha, Trung Quang ^b   Popa, Mihaela ^c   Hovland, Randi ^d   Bruserud, Eystein ^b,d   Gjertsen, Bjørn Tore ^b,d   Kuo, Ya Huei ^a   Chen, Wenyong ^a   Lain, Sonia ^e   McCormack, Emmet ^b,d   Bhatia, Ravi ^a   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c KinN Therapeutics AS   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD135 ANTIGEN; PHOSPHOTRANSFERASE INHIBITOR; QUIZARTINIB; SIRTUIN 1; TV6; UNCLASSIFIED DRUG; BENZOTHIAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CD34 ANTIGEN; MYC PROTEIN; PROTEIN BINDING; THIOL ESTER HYDROLASE; USP22 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL KILLING; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; STEM CELL; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENE DUPLICATION; GENE REGULATORY NETWORK; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; SCID MOUSE;

ANIMALS; ANTIGENS, CD34; BENZOTHIAZOLES; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; GENE KNOCKDOWN TECHNIQUES; GENE REGULATORY NETWORKS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE, SCID; NEOPLASTIC STEM CELLS; PHENYLUREA COMPOUNDS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; SIRTUIN 1; THIOLESTER HYDROLASES;

EID: 84916891627     PISSN: 19345909     EISSN: 18759777     Source Type: Journal    
DOI: 10.1016/j.stem.2014.08.001     Document Type: Article

References (46)

1. Alcaín, F.J., and Villalba, J.M. (2009). Sirtuin inhibitors. Expert Opin. Ther. Pat. 19, 283-294.
2. Armour, S.M., Bennett, E.J., Braun, C.R., Zhang, X.Y., McMahon, S.B., Gygi, S.P., Harper, J.W., and Sinclair, D.A. (2013). A high-confidence interaction map identifies SIRT1 as a mediator of acetylation of USP22 and the SAGA coactivator complex. Mol. Cell. Biol. 33, 1487-1502.
3. Bradbury, C.A., Khanim, F.L., Hayden, R., Bunce, C.M., White, D.A., Drayson, M.T., Craddock, C., and Turner, B.M. (2005). Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19, 1751-1759.
4. Brooks, C.L., and Gu, W. (2009). How does SIRT1 affect metabolism, senescence and cancer? Nat. Rev. Cancer 9, 123-128.
5. Bullinger, L., Döhner, K., Kranz, R., Stirner, C., Fröhling, S., Scholl, C., Kim, Y.H., Schlenk, R.F., Tibshirani, R., Döhner, H., and Pollack, J.R. (2008). An FLT3 gene-expression signature predicts clinical outcomeinnormal karyotype AML. Blood 111, 4490-4495.
6. Choudhary, C., Olsen, J.V., Brandts, C., Cox, J., Reddy, P.N., Böhmer, F.D., Gerke, V., Schmidt-Arras, D.E., Berdel, W.E., Müller-Tidow, C., et al. (2009). Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol. Cell 36, 326-339.
7. Chu, S.H., Heiser, D., Li, L., Kaplan, I., Collector, M., Huso, D., Sharkis, S.J., Civin, C., and Small, D. (2012). FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. Cell Stem Cell 11, 346-358.
8. Dan, L., Klimenkova, O., Klimiankou, M., Klusman, J.H., van den Heuvel-Eibrink, M.M., Reinhardt, D., Welte, K., and Skokowa, J. (2012). The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica 97, 551-559.
9. Eppert, K., Takenaka, K., Lechman, E.R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K.H., Poeppl, A., Ling, V., Beyene, J., et al. (2011). Stem cell gene expression programs influence clinical outcome inhuman leukemia. Nat. Med. 17, 1086-1093.
10. Han, M.K., Song, E.K., Guo, Y., Ou, X., Mantel, C., and Broxmeyer, H.E. (2008). SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2, 241-251.
11. Horton, S.J., and Huntly, B.J. (2012). Recent advancesin acute myeloid leukemia stem cell biology. Haematologica 97, 966-974.
12. Jordan, C.T., Upchurch, D., Szilvassy, S.J., Guzman, M.L., Howard, D.S., Pettigrew, A.L., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D.A., et al. (2000). The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777-1784.
13. Kim, K.T., Baird, K., Davis, S., Piloto, O., Levis, M., Li, L., Chen, P., Meltzer, P., and Small, D. (2007). Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. Br. J. Haematol. 138, 603-615.
14. Kindler, T., Lipka, D.B., and Fischer, T. (2010). FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116, 5089-5102.
15. Leko, V., Varnum-Finney, B., Li, H., Gu, Y., Flowers, D., Nourigat, C., Bernstein, I.D., and Bedalov, A.(2012). SIRT1isdispensable for function ofhematopoietic stem cells in adult mice. Blood 119, 1856-1860.
16. Levis, M. (2011). FLT3/ITD AML and the law of unintended consequences. Blood 117, 6987-6990.
17. Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T.L., Chen, W., and Bhatia, R. (2012). Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21, 266-281.
18. Lin, Z., Yang, H., Kong, Q., Li, J., Lee, S.M., Gao, B., Dong, H., Wei, J., Song, J., Zhang, D.D., and Fang, D. (2012). USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol. Cell 46, 484-494.
19. Long, J., Parkin, B., Ouillette, P., Bixby, D., Shedden, K., Erba, H., Wang, S., and Malek, S.N. (2010). Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 116, 71-80.
20. MacCallum, S.F., Groves, M.J., James, J., Murray, K., Appleyard, V., Prescott, A.R., Drbal, A.A., Nicolaou, A., Cunningham, J., Haydock, S., et al. (2013). Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Sci. Rep. 3, 1275.
21. Majeti, R., Chao, M.P., Alizadeh, A.A., Pang, W.W., Jaiswal, S., Gibbs, K.D., Jr., van Rooijen, N., and Weissman, I.L. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299.
22. Marshall, G.M., Liu, P.Y., Gherardi, S., Scarlett, C.J., Bedalov, A., Xu, N., Iraci, N., Valli, E., Ling, D., Thomas, W., et al. (2011). SIRT1 promotes N-Myc onco-genesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet. 7, e1002135.
23. McCormack, E., Haaland, I., Vena°s, G., Forthun, R.B., Huseby, S., Gausdal, G., Knappskog, S., Micklem, D.R., Lorens, J.B., Bruserud, O., and Gjertsen, B.T. (2012). Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 26, 910-917.
24. McCormack, E., Mujic, M., Osdal, T., Bruserud, Ø., and Gjertsen, B.T. (2013). Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood 121, e34-e42.
25. Menssen, A., Hydbring, P., Kapelle, K., Vervoorts, J., Diebold, J., Luscher, B., Larsson, LG., and Hermeking, H. (2012). The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc. Natl. Acad. Sci. USA 109, E187-E196.
26. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., and Misawa, S. (1996). Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10, 1911-1918.
27. O'Donnell, M.R., Abboud, C.N., Altman, J., Appelbaum, F.R., Arber, D.A., Attar, E., Borate, U., Coutre, S.E., Damon, L.E., Goorha, S., et al. (2012). Acute myeloid leukemia. J. Natl. Compr. Canc. Netw. 10, 984-1021.
28. Ou, X., Chae, H.D., Wang, R.H., Shelley, W.C., Cooper, S., Taylor, T., Kim, Y.J., Deng, C.X., Yoder, M.C., and Broxmeyer, H.E. (2011). SIRT1 deficiency compromises mouse embryonic stem cell hematopoietic differentiation, and embryonic and adult hematopoiesis in the mouse. Blood 117, 440-450.
29. Patel, J.P., Gonen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079-1089.
30. Sasca, D., Hahnel, P.S., Szybinski, J., Khawaja, K., Kriege, O., Pante, S.V., Bullinger, L, Strand, S., Strand, D., Theobald, M., and Kindler, T. (2014). SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood 124, 121-133.
31. Schrecengost, R.S., Dean, J.L, Goodwin, J.F., Schiewer, M.J., Urban, M.W., Stanek, T.J., Sussman, R.T., Hicks, J.L, Birbe, R.C., Draganova-Tacheva, R.A., et al. (2014). USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Res. 74, 272-286.
32. Schuhmacher, M., Kohlhuber, F., Holzel, M., Kaiser, C, Burtscher, H., Jarsch, M., Bornkamm, G.W., Laux, G., Polack, A., Weidle, U.H., and Eick, D. (2001). The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 29, 397-406.
33. Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R.S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. USA 105, 3933-3938.
34. Singh, S.K., Williams, C.A., Klarmann, K., Burkett, S.S., Keller, J.R., and Oberdoerffer, P. (2013). Sirt1 ablation promotes stress-induced loss of epige-netic and genomic hematopoietic stem and progenitor cell maintenance. J. Exp. Med. 210, 987-1001.
35. Smith, C.C., Wang, Q., Chin, C.S., Salerno, S., Damon, L.E., Levis, M.J., Perl, A.E., Travers, K.J., Wang, S., Hunt, J.P., et al. (2012). Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485, 260-263.
36. Tang, Y., Zhao, W., Chen, Y., Zhao, Y., and Gu, W. (2008). Acetylation is indispensable for p53 activation. Cell 133, 612-626.
37. Valk, P.J., Verhaak, R.G., Beijen, M.A., Erpelinck, C.A., Barjesteh van Waalwijk van Doorn-Khosrovani, S., Boer, J.M., Beverloo, H.B., Moorhouse, M.J., van der Spek, P.J., Löwenberg, B., and Delwel, R. (2004). Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617-1628.
38. van der Lugt, N.M., Domen, J., Verhoeven, E., Linders, K., van der Gulden, H., Allen, J., and Berns, A. (1995). Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J. 14, 2536-2544.
39. Vaziri, H., Dessain, S.K., Ng Eaton, E., Imai, S.I., Frye, R.A., Pandita, T.K., Guarente, L., and Weinberg, R.A. (2001). hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149-159.
40. Wang, R.H., Sengupta, K., Li, C., Kim, H.S., Cao, L., Xiao, C., Kim, S., Xu, X., Zheng, Y., Chilton, B., et al. (2008a). Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14, 312-323.
41. Wang, R.H., Zheng, Y., Kim, H.S., Xu, X., Cao, L., Luhasen, T., Lee, M.H., Xiao, C., Vassilopoulos, A., Chen, W., et al. (2008b). Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol. Cell 32, 11-20.
42. Wang, Z., Yuan, H., Roth, M., Stark, J.M., Bhatia, R., and Chen, W.Y. (2013). SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene 32, 589-598.
43. Yang, Q., Chen, L.S., Neelapu, S.S., Miranda, R.N., Medeiros, L.J., and Gandhi, V. (2012). Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 120, 3491-3500.
44. Yuan, J., Minter-Dykhouse, K., and Lou, Z. (2009). A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J. Cell Biol. 185, 203-211.
45. Yuan, H., Wang, Z., Li, L., Zhang, H., Modi, H., Horne, D., Bhatia, R., and Chen, W. (2012). Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119, 1904-1914.
46. Zhang, X.Y., Varthi, M., Sykes, S.M., Phillips, C., Warzecha, C., Zhu, W., Wyce, A., Thorne, A.W., Berger, S.L., and McMahon, S.B. (2008). The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol. Cell 29, 102-111.